Development of SLN and NLC Enriched Hydrogels for Transdermal Delivery of Nitrendipine: In Vitro and In Vivo Characteristics

REFERENCES

• M. Aqil, A. Ali, Y. Sultana, K. Dubey, K. A. Najmi, and K. K. Pillai. (2006). In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: A technical note. AAPS PharmSciTech 7:E1.
   PubMedGoogle Scholar
• M. Aqil, Y. Sultana, A. Ali, K. Dubey, K. A. Najmi, and K. K. Pillai. (2004). Transdermal drug delivery system of a beta blocker: Design, in vitro, and in vivo characterization. Drug Deliv. 11:27–31.
   PubMed Web of Science ®Google Scholar
• K. Bunjes, M. H. J. Koch, and K. Westesen. (2003). Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci. 92:1509–1520.
   PubMed Web of Science ®Google Scholar
• H. Bunjes, K. Westesen, and M. J. H. Koch. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129:159–173.
   Web of Science ®Google Scholar
• R. Cavalli, D. Aquilano, M. E. Carrlotti, and M. R. Gasco. (1995). Study by X-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur. J. Pharm. Biopharm. 41:329–333.
   Web of Science ®Google Scholar
• R. Cavalli, O. Caputo, M. E. Carlotti, M. Trotta, C. Scarnecchia, and M. R. Gasco. (1997). Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148:47–54.
   Web of Science ®Google Scholar
• T. de Vringer 1992. Topical preparation containing a suspension of solid lipid particles. European Patent No. 91200664.
   Google Scholar
• T. de Vringer, and H. A. G. de Ronde. (1995). Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci. 84:466–472.
   PubMed Web of Science ®Google Scholar
• J. H. Draize, G. Woodward, and H. O. Calvery. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82:377–379.
   Web of Science ®Google Scholar
• C. Freitas (1998). Feste lipid nanopartikel (SLN): Mechanismen der physikalischen destabilisierung und stabilisierung. PhD Thesis. Freie Universität Berlin, Berlin, Germany.
   Google Scholar
• C. Freitas, and R. H. Müller. (1999). Stability determination of solid lipid nanoparticles (SLNs) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 16:59–71.
   PubMed Web of Science ®Google Scholar
• V. Jenning, G. E. Hildebrand, A. Gysler, R. H. Müller, M. Schäfer- Korting, and S. Gohla. (1999). Solid lipid nanoparticles (SLN) for topical application: Occlusive properties. Proc. Int. Symp. Control. Rel. Bioact. Mater. 26:405–406.
   Google Scholar
• V. Jenning, K. Mader, and S. H. Gohla. (2000). Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: A 1h NMR study. Int. J. Pharm. 205:15–21.
   PubMed Web of Science ®Google Scholar
• V. Jenning, M. Schäfer-Korting, and S. Gohla. (2000). Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties. J. Control. Release 66:115–126.
   PubMed Web of Science ®Google Scholar
• V. Jenning, A. F. Thünemann, and S. H. Gohla. (2000). Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199:167–177.
   PubMed Web of Science ®Google Scholar
• S. Katayose, and K. Kataoka. (1997). Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug. Chem. 8:702–707.
   PubMed Web of Science ®Google Scholar
• D. Kobayashi, T. Matsuzawa, K. Sugibayashi, Y. Morimoto, M. Kobayashi, and M. Kimura. (1993). Feasibility of use of several cardiovascular agents in transdermal therapeutic systems with l-menthol-ethanol system on hairless rat and human skin. Biol. Pharm. Bull. 16:254–258.
   PubMed Web of Science ®Google Scholar
• R. S. Langer, and A. Peppas. (1981). Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 2:201–214.
   PubMed Web of Science ®Google Scholar
• W. Mehnert, and K. Mäder. (2001). Solid lipid nanoparticles—production, characterization and applications. Adv. Drug Deliv. Rev. 47:165–196.
   PubMed Web of Science ®Google Scholar
• A. Z. Mühlen, E. Z. Mühlen, H. Niehus, and W. Mehnert. (1996). Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res. 13:1411–1416.
   PubMed Web of Science ®Google Scholar
• R. H. Muller, and A. Dingler. (1998). The next generation after the liposomes: Solid lipid nanoparticles (SLN, lipopearls) as dermal carriers in cosmetics. Eurocosmetics 7/8:19–26.
   Google Scholar
• B. W. Müller, J. S. Lucks, B. Stampa, and R. H. Müller. (1990). Effect of antiflocculants on suspension stability and size distribution. Pharm. Ind. 52:789–793.
   Web of Science ®Google Scholar
• R. H. Müller, W. Mehnert, J. S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C. Freitas, and D. Rühl. (1995). Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:62–69.
   Web of Science ®Google Scholar
• R. H. Müller, M. Radtke, and S. A. Wissing. (2002a). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54:S131–S155.
   PubMed Web of Science ®Google Scholar
• R. H. Müller, M. Radtke, and S. A. Wissing. (2002b). Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242:121–128.
   PubMed Web of Science ®Google Scholar
• R. H. Müller, M. Radtke, and S. A. Wissing (2004). Solid lipid nanoparticles and nanostructured lipid carriers. In H. S. Nalwa. (Ed.), Encyclopedia of nanoscience and nanotechnology (pp. 43–56 ). California, USA: American Scientific Publishers.
   Google Scholar
• R. H. Müller, and S. A. Wissing (2003). Lipopearls for topical delivery of active compounds and controlled release. In M. J. Rathbone, J. Hadgraft, and M. S. Roberts (Eds.), Modified-release drug delivery systems (pp. 571–587 ) New York, Basel, and Hong Kong: Marcel Dekker.
   Google Scholar
• S. Mutalik, and N. Udupa. (2004). Glibenclamide transdermal patches: Physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J. Pharm. Sci. 93:1577–1594.
   PubMed Web of Science ®Google Scholar
• A. Namdeo, and N. K. Jain. (2002). Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. J. Control. Release 82:223–236.
   PubMed Web of Science ®Google Scholar
• C. Olbrich, O. Kayser, and R. H. Muller. (2002). Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)—effect of surfactants, storage time and crystallinity. Int. J. Pharm. 237:119–128.
   PubMed Web of Science ®Google Scholar
• D. W. Osborne, and A. H. Amann (1990). Topical drug delivery formulations. New York and Basel: Marcel Dekker.
   Google Scholar
• M. Saravanan, K. Bhaskar, G. Maharajan, and K. Sadasivan Pillai. (2004). Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres. Int. J. Pharm. 283:71–82.
   PubMed Web of Science ®Google Scholar
• K. Westesen, H. Bunjes, and M. H. J. Koch. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 48:223–236.
   Web of Science ®Google Scholar
• S. A. Wissing, A. Lippacher, and R. H. Muller. (2001). Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J. Cosmet. Sci. 52:313–323.
   PubMed Web of Science ®Google Scholar
• S. C. Yang, and J. B. Zhu. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm. 28 (3):265–274.
   PubMed Web of Science ®Google Scholar